KPT-330, a potent and selective exportin-1 (XPO-1) inhibitor, shows antitumor effects modulating the expression of cyclin D1 and survivin in prostate cancer models

The nuclear retention of transcription factor FOXO3a correlates with a DNA damage response and increased glutamine synthetase expression by astrocytes suggesting a neuroprotective role in the ageing brain

(2015) Adeline Fluteau et al.   NEUROSCIENCE LETTERS

Anti-tumor activity of selective inhibitors of XPO1/CRM1-mediated nuclear export in diffuse malignant peritoneal mesothelioma: the role of survivin

(2015) Michelandrea De Cesare et al.   Oncotarget

Selective inhibitors of nuclear export (SINE) as novel therapeutics for prostate cancer

(2015) Janet Mendonca et al.   Oncotarget

NF- B Gene Signature Predicts Prostate Cancer Progression

(2014) R. Jin et al.   CANCER RESEARCH

XPO1/CRM1-Selective Inhibitors of Nuclear Export (SINE) reduce tumor spreading and improve overall survival in preclinical models of prostate cancer (PCa)

(2014) Giovanni Gravina et al.   Journal of Hematology & Oncology

Nucleo-cytoplasmic transport as a therapeutic target of cancer

(2014) Giovanni Luca Gravina et al.   Journal of Hematology & Oncology

FoxO3a Nuclear Localization and Its Association with β-Catenin and Smads in IFN-α-Treated Hepatocellular Carcinoma Cell Lines

(2014) María Paula Ceballos et al.   JOURNAL OF INTERFERON AND CYTOKINE RESEARCH

XPO1 (CRM1) Inhibition Represses STAT3 Activation to Drive a Survivin-Dependent Oncogenic Switch in Triple-Negative Breast Cancer

(2014) Y. Cheng et al.   MOLECULAR CANCER THERAPEUTICS

Novel Small Molecule XPO1/CRM1 Inhibitors Induce Nuclear Accumulation of TP53, Phosphorylated MAPK and Apoptosis in Human Melanoma Cells

(2014) Jennifer Yang et al.   PLoS One

Torc1/Torc2 inhibitor, Palomid 529, enhances radiation response modulating CRM1-mediated survivin function and delaying DNA repair in prostate cancer models

(2014) Giovanni Luca Gravina et al.   PROSTATE

Nucleoporins and nucleocytoplasmic transport in hematologic malignancies

(2014) Akiko Takeda et al.   SEMINARS IN CANCER BIOLOGY

Clinical translation of nuclear export inhibitors in cancer

(2014) William T. Senapedis et al.   SEMINARS IN CANCER BIOLOGY

Knockdown of CRM1 inhibits the nuclear export of p27Kip1 phosphorylated at serine 10 and plays a role in the pathogenesis of epithelial ovarian cancer

(2013) You Wang et al.   CANCER LETTERS

Cyclin D1 overexpression perturbs DNA replication and induces replication-associated DNA double-strand breaks in acquired radioresistant cells

(2013) Tsutomu Shimura et al.   CELL CYCLE

Valeriana jatamansi Constituent IVHD-valtrate As a Novel Therapeutic Agent to Human Ovarian Cancer: in vitro and in vivo Activities and Mechanisms

(2013) Xiaoguang Li et al.   CURRENT CANCER DRUG TARGETS

CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications

(2013) Y-T Tai et al.   LEUKEMIA

p53 SUMOylation promotes its nuclear export by facilitating its release from the nuclear export receptor CRM1

(2013) Aleixo Santiago et al.   MOLECULAR BIOLOGY OF THE CELL

Loss of Survivin in the Prostate Epithelium Impedes Carcinogenesis in a Mouse Model of Prostate Adenocarcinoma

(2013) Helty Adisetiyo et al.   PLoS One

CRM1 Inhibition Sensitizes Drug Resistant Human Myeloma Cells to Topoisomerase II and Proteasome Inhibitors both In Vitro and Ex Vivo

(2013) Joel G. Turner et al.   Journal of Cancer

Novel selective inhibitors of nuclear export CRM1 antagonists for therapy in mantle cell lymphoma

(2012) Kejie Zhang et al.   EXPERIMENTAL HEMATOLOGY

Targeting the Fas/FasL signaling pathway in cancer therapy

(2012) María Villa-Morales et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Selective Inhibitors of Nuclear Export Block Pancreatic Cancer Cell Proliferation and Reduce Tumor Growth in Mice

(2012) Asfar S. Azmi et al.   GASTROENTEROLOGY

Distinct expression and activity of GSK-3α and GSK-3β in prostate cancer

(2012) R. Siobhan Darrington et al.   INTERNATIONAL JOURNAL OF CANCER

Consensus Induced Fit Docking (cIFD): methodology, validation, and application to the discovery of novel Crm1 inhibitors

(2012) Ori Kalid et al.   JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN

CRM1 Blockade by Selective Inhibitors of Nuclear Export Attenuates Kidney Cancer Growth

(2012) Hiromi Inoue et al.   JOURNAL OF UROLOGY

Nuclear export of proteins and drug resistance in cancer

(2011) Joel G. Turner et al.   BIOCHEMICAL PHARMACOLOGY

CBS9106 is a novel reversible oral CRM1 inhibitor with CRM1 degrading activity

(2011) K. Sakakibara et al.   BLOOD

GSK-3b inhibition: At the crossroad between Akt and mTOR constitutive activation to enhance cyclin D1 protein stability in mantle cell lymphoma

(2011) Jessica Dal Col et al.   CELL CYCLE

Deciphering the Role of Forkhead Transcription Factors in Cancer Therapy

(2011) Jer-Yen Yang et al.   CURRENT DRUG TARGETS

The TORC1/TORC2 inhibitor, Palomid 529, reduces tumor growth and sensitizes to docetaxel and cisplatin in aggressive and hormone-refractory prostate cancer cells

(2011) G. L. Gravina et al.   ENDOCRINE-RELATED CANCER

Acquired Radioresistance of Cancer and the AKT/GSK3β/cyclin D1 Overexpression Cycle

(2011) Tsutomu SHIMURA   JOURNAL OF RADIATION RESEARCH

Downregulation of both p21/Cip1 and p27/Kip1 produces a more aggressive prostate cancer phenotype

(2010) Srirupa Roy et al.   CELL CYCLE

CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts

(2010) Christophe Ginestier et al.   JOURNAL OF CLINICAL INVESTIGATION

Identification of Nuclear Export Inhibitors with Potent Anticancer Activity In vivo

(2009) S. C. Mutka et al.   CANCER RESEARCH

Expression of the nuclear export protein chromosomal region maintenance/exportin 1/Xpo1 is a prognostic factor in human ovarian cancer

(2008) Aurelia Noske et al.   CANCER

Glycogen synthase kinase 3β induces apoptosis in cancer cells through increase of survivin nuclear localization

(2008) Jiansha Li et al.   CANCER LETTERS

The Karyopherin proteins, Crm1 and Karyopherin β1, are overexpressed in cervical cancer and are critical for cancer cell survival and proliferation

(2008) Pauline J. van der Watt et al.   INTERNATIONAL JOURNAL OF CANCER